

NIH Public Access

Author Manuscript

Mol Cell Biochem. Author manuscript; available in PMC 2009 September 9.

Published in final edited form as:

Mol Cell Biochem. 2009 August ; 328(1-2): 9–16. doi:10.1007/s11010-009-0067-8.

Old target new approach: an alternate NF-κB activation pathway via translation inhibition

Csaba F. Lászlí and **Shiyong Wu**

Department of Chemistry and Biochemistry, Edison Biotechnology Institute, Ohio University, Athens, OH 45701, USA

Csaba F. Lászlí: ; Shiyong Wu: wus1@ohio.edu

Abstract

Activation of the transcription factor NF-κB is a highly regulated multi-level process. The critical step during activation is the release from its inhibitor IκB, which as any other protein is under the direct influence of translation regulation. In this review, we summarize in detail the current understanding of the impact of translational regulation on NF-κB activation. We illustrate a newly developed mechanism of eIF2α kinase-mediated IκB depletion and subsequent NF-κB activation. We also show that the classical NF- κ B activation pathways occur simultaneously with, and are complemented by, translational down regulation of the inhibitor molecule IκB, the importance of one or the other being shifted in accordance with the type and magnitude of the stressing agent or stimuli.

Keywords

Inhibitor of nuclear factor κB; Nuclear factor κB; Eukaryotic initiation factor 2; eIF2α kinase; IκB kinase

History

In 1986 David Baltimore's laboratory discovered a nuclear protein in mature B cells that binds to a 10 nucleotide stretch of double-stranded DNA in the κ immunoglobulin light chain enhancer (GGGACTTTCC) [1]. It was soon proven that this nuclear factor had a role in the mediated expression of the κ light chain and that it's localization in the nuclei is associated with different cellular stimuli [2]. Further studies have shown that NF-κB is involved in the regulation of the expressions of many genes that are mostly related to the immune and inflammatory response, along with genes determining developmental processes, cellular growth, and apoptosis [3,4].

NF-κB family members

The mammalian NF-κB family is composed of five members, i.e., p65 (RelA), RelB, NF-κB1 (p50 and its precursor p105), c-Rel, and NF-κB2 (p52 and its precursor p100) [5,6]. They all have in common a 300 amino acid Rel homology domain (RHD) located close to the N terminus of the protein [7]. However, while p65 and p50 were found to be universally present, the other three members (RelB, cRel, and p52) were suggested to be only expressed in lymphoid cells [8]. The RHD contains sequences are accountable for the homo- or hetero-dimerization of the

[©] Springer Science+Business Media, LLC. 2009

Correspondence to: Shiyong Wu, wus1@ohio.edu.

family members. Of the five members, only three p65, RelB, and c-Rel contain a *trans*activation domain (TAD), which is needed to promote transcription by facilitating the employment of activators and banishment of repressors [9]. Subsequently homodimers of the other two members, p52 and p50 are unable to activate transcription. Instead, they attenuate expression of target genes.

The role of IκB in regulation of NF-κB activation

The activity of NF-κB is regulated at multiple levels. The best known regulatory step is the cytoplasmic to nuclear transport of activated NF-κB p65:p50 heterodimer [10,11]. Without stimulation, cytoplasmic compartmentalization of NF-κB in cells is due to binding through the RHD to a member from the family of proteins called inhibitor of NF-κB (IκB). IκB family consists of IkB α , IkB β , IkB ϵ , IkB γ , BCL-3, and the two NF-kB precursors p100 and p105 [12,13]. IkB α and IkB β achieve the cytoplasmic localization by masking the nuclear localization sequence (NLS) of amino acids on the NF-κB p65 subunit [14–16]. Failure to mask the NLS of the p65 subunit in addition to the existence of a nuclear export sequence (NES) on IκBα and p65, results in the constant shuttling of IκBα:p65:p50 complexes between the cytoplasm and nucleus. On the other hand, IκBβ:p65:p50 complexes are restricted to the extra nuclear compartment, this phenomena adding to the complexity of NF-κB regulation.

The role of kinases in regulation of NF-κB activation

After removing IκB , a second level of regulation is conferred mainly by stimulus-induced phosphorylation of NF-κB [17]. A protein kinase A (PKA) phosphorylation site was identified on both p65 and c-Rel at Ser 276, located 25 amino acids from the NLS, inside the Rel homology domain (RHD) [18]. Over-expression of PKA leads to a higher DNA-binding activity of NFκB. This is mainly due to the fact that phosphorylated Ser 276 inhibits intermolecular association with inhibitors, thus facilitating nuclearization and DNA binding [17,19]. The same phosphorylation also promotes interaction with coactivator CREB binding protein (CBP/p300) [18]. A similar mechanism of NF- κ B activation was identified during tumor necrosis factor α (TNFα) stimulation when p65 phosphorylation occurred at Ser 529 mediated by casein kinase II (CKII) [20,21]. Also during TNFα stimulation another activating phosphorylation occurs at Ser 536 by none other than IKK [22]. It is worthy to note that the same catalytic activity of IKK is required for IκB phosphorylation followed by ubiquitination and NF-κB activation by direct phosphorylation, fact that adds to the complexity of IKK mediated NF-κB activation [23]. The activity of stimulated NF-κB is down regulated by a feedback pathway through the newly synthesized IκBα, one of the first genes activated by NF-κB. The re-synthesized IκBα enters the nucleus, binds to NF-κB and exports it to the cytosol, thus inhibiting its functionality [24,25].

The classical NF-κB activation mechanism

Upon extra- or intracellular stimulation the IKBs are phosphorylated by an IKB kinase (IKK), ubiquitin targeted and undergo proteosomal degradation thus automatically exposing the NLS necessary for NF-κB nuclear localization [26,27]. IKK is a 700 kDa protein complex consisting of two catalytic subunits (IKK α and IKK β) and a regulatory subunit (IKK γ or NEMO—NFκB essential modulator) [28–30]. Activation of the catalytic subunits takes place by phosphorylation followed by intra- and intermolecular *trans*-autophosphorylation releasing their kinase domains. A host of NF-κB inducers have been recognized so far, they consist of but are not limited to proinflamatory cytokines (TNFα, IL-1, etc.), double-stranded RNA (dsRNA), viruses and a variety of cell stressors like ultraviolet light (UV), reactive oxygen species (ROS), and genotoxic agents [7,31]. Some of NF-κB activators, such as cytokines, achieve activation through the classical activation mechanism (Fig. 1), while others like UV, ROS, heat shock, and hypoxia regulate NF-κB through much more branched and complex

cellular pathways [32–35]. The common feature of these general inducers is that they cause translation inhibition as a defense cellular response through their noxious effects.

The impact of translation initiation on NF-κB activation

An entirely different approach to NF-κB activation is provided by translational regulation via the eukaryotic initiation factor 2 (eIF2). During the initiation step of translation, eIF2 forms a complex with GTP and Met-tRNA forming a ternary complex, which associated with the small ribosomal unit contributes to the selection of the start codon. The release from the ribosome is achieved at the expense of hydrolization of GTP to GDP. In order to restart the initiation cycle the guanine exchange factor eIF2B refreshes the eIF2-GDP to eIF2-GTP [36]. The phosphorylation on Ser 51 of the α subunit of eIF2 (eIF2 α) stabilizes the eIF2-GDP-eIF2B initiation complex preventing GDP-GTP exchange, thus halting the translational initiation process [37,38]. The eIF2 α phosphorylation inhibits initiation of protein synthesis at a general level, allowing only the selective translation of some proteins that are required for mounting a stress response [39,40].

Key players in translational regulation are a host of serine–threonine kinases that can phosphorylate the Ser 51 of eIF2α. Four eIF2α kinases (EIF2AKs) have been identified. While each of the EIF2AKs has its own specific inducers, some stimulus such as UV and hypoxia also activate one or more of the kinases (Fig. 2).

EIF2AK1, known as the heme-regulated inhibitor kinase (HRI), is a critical component during erythroid maturation that regulates the stoichiometric ratio of hemoglobin components, i.e., α-globin, β-globin, and heme [41]. Two separate heme binding sites were identified in HRI [42]. HRI is activated by heme deficiency in multi-stages through series of *auto*phosphorylations [43]. The phosphorylation of HRI first stabilizes its monomer that lacks $eIF2\alpha$ kinase activity, but has first heme-binding site occupied. Further phosphorylation of HRI induces the dimerization and confers heme sensitivity [44]. During high heme concentrations, heme binds to the second binding site inhibiting HRI kinase activity thus allowing for protein and implicitly hemoglobin translation [45]. In the situation of insufficient heme accumulation the second heme-binding site remains unoccupied, which leads to the induction of HRI kinase activity and inhibition of translation by $eIF2\alpha$ phosphorylation [46]. While heme deficiency leads to activation of NF-κB, there is no direct evidence yet to show that the translation inhibition is involved in the activation of signaling pathways. Besides heme deficiency, other NF-κB activator, such as arsenite-induced oxidative stress and heat shock were also found to activate HRI [47].

EIF2AK2, known as the interferon-induced double-stranded (ds) RNA-dependent protein kinase (PKR), plays a critical role in anti-viral defense [48]. The binding of the dsRNA exposes an ATP-binding site inducing dimerization and subsequent *auto*-phosphorylation leading to an active form of PKR [49–51].Avariety of stimuli, like growth factors and cytokines, activate PKR independently of dsRNA through PKR-associated activator proteins [52,53]. Initially, PKR was suggested to directly phosphorylate IkB [54]. However, the hypothesis was challenged by results showing that kinase inactivated PKR is still capable of activating NFκB [55]. Furthermore, co-immunoprecipitation analysis demonstrated that PKR forms a complex with IKK independent of its ability of activation of NF-κB [55,56]. Based on these findings, it was proposed that PKR binds to the IKK complex or acts upstream facilitating IKK to phosphorylate IκBα at serines 32 and 36 [55–58]. Conversely, it has also been reported by others that PKR mutants that are unable to activate NF-κB still preserve their ability to coimmunoprecipitate with IKK [56]. While the roles of PKR and its catalytic activity in NF-κB activation remain controversial [55–58], several PKR activators, such as dsRNA and interferon γ (IFNγ) have been shown to induce NF-κB activation. Regardless of PKRs' inability to activate

NF-κB independently of its kinase function, activated PKR does nevertheless phosphorylate $eIF2\alpha$ thus inhibiting global translation and potentially can decrease IKB synthesis.

EIF2AK3, also known as the PKR like endoplasmic reticulum (ER) related kinase (PERK), is an ER membrane localized kinase [59–61]. Its inactive monomer state is stabilized by an ER chaperone immunoglobulin (Ig) heavy chain binding protein (BiP). Under ER-stress, BiP releases PERK, which undergoes dimerization, *trans*-phosphorylation and sequentially activation [60–63]. Outside or inside perturbations negatively affect protein-folding process in ER resulting in an accumulation of malfolded proteins, which triggers the unfolded protein response (UPR). While UPR transcriptionally activates the expression of ER chaperone to facilitate the folding process, it translationally inhibits general protein synthesis through phosphorylating eIF2 α to reduce the accumulation of newly synthesized proteins in ER [64]. The converging point between the accumulation of unfolded proteins and global translation inhibition by eIF2α phosphorylation was determined to be PERK [59,65]. The PERK-mediated $eIF2\alpha$ phosphorylation and translation inhibition was shown to be directly involved in ERstress-mediated NF-κB activation upon various stimuli, such as hypoxia, UV, and thapsigargin [33,34,66–69].

EIF2AK4 is also known as the amino acid starvation dependent general control of amino acid biosynthesis kinase (GCN2) [70,71]. It is an amino acid abundance controlled eIF2 α kinase, which is activated during amino acid starvation. Its specific role is to halt protein translation while activating the translation of factors that are needed in amino acid synthesis [61,72]. The activation mechanism involves a histidyl-tRNA synthase (HisRS) homologous sequence, where the excess of uncharged tRNAs bind during amino acid deprivation [73]. A C-terminal RNA binding region is also required for its dimerization, activation, and association with ribosome [74,75]. The GCN2-mediated eIF2α phosphorylation and translation inhibition was shown to be directly involved in amino acid starvation induced NF-κB activation [66]. Besides nutritional stresses, the HisRS similar sequence also allows for activation by other stresses, such as UV and proteosome inhibition [71,72]. While there is no evidence yet to show that GCN2 is directly involved in NF-κB activation upon proteosome inhibition, it has been demonstrated that GCN2 mediates UV-induced NF-κB activation [76].

Besides eIF2 α another initiation factor was recently also found to regulate NF- κ B. This is the eukaryotic initiation factor 4E (eIF4E), which facilitates translation by binding to the 5′ cap structure of the mRNA. Although for now the studies fall short of providing any details for the activation mechanism, they offer other possible alternatives to the classical NF-κB activation pathway [77].

Regulation of IκB turnover

NF-κB is stranded in the cytoplasm bound by its inhibitor protein IκB. Even though both IκBα and IκBβ are able to inhibit NF-κB, it is IκBα that bears the major role in regulating its activation [78]. NF-κB is a transcription factor that has a fast response time in order to react promptly to cellular stress. In order to achieve this fast activation, the IκB levels are tightly and rapidly regulated [79]. While activation of receptor signaling cascade, such as TNFα and interleukin-1 (IL-1), often leads to phosphorylation, ubiquitination, and proteolysis of IκB , the more general cellular stimulus, such as UV and hypoxia, also possess the ability to induce translational inhibition of IκB synthesis.

IκB degradation occurs through two mechanisms, i.e., a signal-dependent and signalindependent (basal degradation) process [80]. IκB turnover is tightly linked to its structural domains. The centrally located ankyrin repeats are necessary for NF-κB binding and the two terminal regions are implicated in the degradation of IκB . The N-terminal sequence contains two IKK phosphorylation sites Ser 32 and 36 [81–84] and two ubiquitination sites Lys 21 and

22 [85,86]. The phosphorylation and ubiquitination of these sites promote IκB degradation in the 26S proteosome. The C-terminal region contains a PEST domain (Pro, Glu, Asp, Ser, and Thr rich regions), which is associated in general with high turnover proteins [87]. The PEST site in addition to multiple casein kinase II (CKII) phosphorylation sites on the C-terminal region are needed for both signal-induced degradation [84,88,89] and basal turnover of IκB [17,82,90,91].

The rate of degradation of IκB is also very much influenced by its association with NF-κB. Free IκB has a 30–40 min half-life, but the NF-κB associated one has a fivefold longer degradation time [92–95]. Free IκB constitutes only a 15% fraction of the total cellular IκB [92], and is a weak substrate for IKK phosphorylation [96]. The basal turnover of free IκB requires the CKII phosphorylation sites while the signal-dependent degradation is induced by IKK phosphorylation. For the NF-κB associated IκB , the basal turnover is also regulated by CKII phosphorylation, while the signal-induced degradation is regulated by both CKII and IKK phosphorylation [80,95,97–99] (Table 1).

While IKK and CKII regulate the removal rate of I_{KB}, the EIF2AKs determine the synthetic rate of IkB. The phosphorylation of eIF2 α by EIF2AK leads to the inhibition of global protein synthesis, including IκB. Since IκB has a relatively high basal turnover rate [79], the inhibition of new IκB synthesis results in a rapid depletion of IκB thus shifting the dynamic balance from NF-κB associated IκB toward free NF-κB and IκB (Fig. 3).

Targeting NF-κB for therapeutic development

NF-κB plays an important role in regulation of the process of innate and adaptive immune responses. Its ability to activate transcription of genes encoding cytokines (e.g., TNFα, IL-1, IL-2, and IL-6), chemokines, adhesion molecules (e.g., ICAM, VCAM, and E-selectin), inducible enzymes (e.g., iNOS and COX-2), and antimicrobial peptides (β defensine) gives it a central role in the overall process of immune response [78]. NF-κB also regulates genes outside the immune system presumably having an anti-apoptotic effect that would give an opportunity to the cell to repair DNA damage. Deregulation of these genes may lead to many diseases, such as cancer, atherosclerosis, arthritis, AIDS, etc. [3]. NF-κB has been a target for the development of therapeutics for many diseases [100]. Since $eIF2\alpha$ phosphorylation also impacts NF- κ B activation, compounds that affect eIF2 α phosphorylation through the aforementioned kinases will be potential therapeutics for treatment of various diseases. Indeed, several ER-stress inducing drugs are already in the spotlight for their ability to induce apoptosis in malignant cells. The chemotherapeutic agents doxorubicin and cisplatin, although known to mainly target DNA, were also shown to induce ER-stress and activate PERK [101–104]. Interferon and TNF- α are both antiviral proteins that have been used in combination with chemo- and radiation therapy and that possess the ability to activate PKR [105,106]. In addition, the potential for successful use of proteasome inhibitors for cancer treatment may be granted by the ability of these compounds to induce apoptosis through the blocking of protein degradation, which implicitly leads to ER-stress. The anti-multiple myeloma drug Velcade (PS-341), for example, which is a proteasome inhibitor, inhibits IκB degradation. In fact, Velcade was also shown to disrupt protein folding in the ER resulting in ER-stress [107– 109]. In summary, elucidating the role of EIF2AK in mediation of NF-κB activation may lead us to a better understanding of the mechanisms of current NF-κB targeting drugs and development of new therapeutics to treat diseases related to deregulation of NF-κB.

Acknowledgments

This work was supported by National Institutes of Health Grant RO1 CA86926 (to S. W.) and R56 CA086928 (to S. W.).

References

- 1. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986;46:705–716. [PubMed: 3091258]doi: [10.1016/0092-8674\(86\)90346-6](http://dx.doi.org/10.1016/0092-8674%2886%2990346-6)
- 2. Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 1986;47:921–928. [PubMed: 3096580]doi: [10.1016/0092-8674\(86\)90807-X](http://dx.doi.org/10.1016/0092-8674%2886%2990807-X)
- 3. Baldwin AS Jr. Series introduction: the transcription factor NF-kappaB and human disease. J Clin Investig 2001;107:3–6. [PubMed: 11134170]doi: [10.1172/JCI11891](http://dx.doi.org/10.1172/JCI11891)
- 4. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002;3:221–227. [PubMed: 11875461]doi: [10.1038/ni0302-221](http://dx.doi.org/10.1038/ni0302-221)
- 5. Duckett CS, Perkins ND, Kowalik TF, et al. Dimerization of NF-KB2 with RelA(p65) regulates DNA binding, transcriptional activation, and inhibition by an I kappa B-alpha (MAD-3). Mol Cell Biol 1993;13:1315–1322. [PubMed: 8441377]
- 6. Grimm S, Baeuerle PA. The inducible transcription factor NF-kappa B: structure–function relationship of its protein subunits. Biochem J 1993;290(Pt 2):297–308. [PubMed: 8452515]
- 7. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004;18:2195–2224. [PubMed: 15371334] doi: [10.1101/gad.1228704](http://dx.doi.org/10.1101/gad.1228704)
- 8. Caamano J, Hunter CA. NF-kappaB family of transcription factors: central regulators of innate and adaptive immune functions. Clin Microbiol Rev 2002;15:414–429. [PubMed: 12097249]doi: [10.1128/CMR.15.3.414-429.2002](http://dx.doi.org/10.1128/CMR.15.3.414-429.2002)
- 9. Zhong H, May MJ, Jimi E, et al. The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol Cell 2002;9:625–636. [PubMed: 11931769]doi: [10.1016/S1097-2765\(02\)00477-X](http://dx.doi.org/10.1016/S1097-2765%2802%2900477-X)
- 10. Baeuerle PA, Baltimore D. Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-kappa B transcription factor. Cell 1988;53:211–217. [PubMed: 3129195]doi: [10.1016/0092-8674 \(88\)90382-0](http://dx.doi.org/10.1016/0092-8674%2888%2990382-0)
- 11. Baeuerle PA, Baltimore D. I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science 1988;242:540–546. [PubMed: 3140380]doi: [10.1126/science.3140380](http://dx.doi.org/10.1126/science.3140380)
- 12. Naumann M, Nieters A, Hatada EN, et al. NF-kappa B precursor p100 inhibits nuclear translocation and DNA binding of NF-kappa B/rel-factors. Oncogene 1993;8:2275–2281. [PubMed: 8336950]
- 13. Naumann M, Wulczyn FG, Scheidereit C. The NF-kappa B precursor p105 and the proto-oncogene product Bcl-3 are I kappa B molecules and control nuclear translocation of NF-kappa B. EMBO J 1993;12:213–222. [PubMed: 8428580]
- 14. Huxford T, Huang DB, Malek S, et al. The crystal structure of the IkappaBalpha/NF-kappaB complex reveals mechanisms of NF-kappaB inactivation. Cell 1998;95:759–770. [PubMed: 9865694]doi: [10.1016/S0092-8674\(00\)81699-2](http://dx.doi.org/10.1016/S0092-8674%2800%2981699-2)
- 15. Malek S, Huxford T, Ghosh G. Ikappa Balpha functions through direct contacts with the nuclear localization signals and the DNA binding sequences of NF-kappaB. J Biol Chem 1998;273:25427– 25435. [PubMed: 9738011]doi: [10.1074/jbc.273.39.25427](http://dx.doi.org/10.1074/jbc.273.39.25427)
- 16. Jacobs MD, Harrison SC. Structure of an IkappaBalpha/NF-kappaB complex. Cell 1998;95:749–758. [PubMed: 9865693]doi: [10.1016/S0092-8674\(00\)81698-0](http://dx.doi.org/10.1016/S0092-8674%2800%2981698-0)
- 17. Naumann M, Scheidereit C. Activation of NF-kappa B in vivo is regulated by multiple phosphorylations. EMBO J 1994;13:4597–4607. [PubMed: 7925300]
- 18. Zhong H, Voll RE, Ghosh S. Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1998;1:661–671. [PubMed: 9660950]doi: [10.1016/S1097-2765\(00\)80066-0](http://dx.doi.org/10.1016/S1097-2765%2800%2980066-0)
- 19. Okazaki T, Sakon S, Sasazuki T, et al. Phosphorylation of serine 276 is essential for p65 NF-kappaB subunit-dependent cellular responses. Biochem Biophys Res Commun 2003;300:807–812. [PubMed: 12559944]doi: [10.1016/S0006-291X\(02\)02932-7](http://dx.doi.org/10.1016/S0006-291X%2802%2902932-7)
- 20. Wang D, Baldwin AS Jr. Activation of nuclear factor-kappaB-dependent transcription by tumor necrosis factor-alpha is mediated through phosphorylation of RelA/p65 on serine 529. J Biol Chem 1998;273:29411–29416. [PubMed: 9792644]doi: [10.1074/jbc.273.45.29411](http://dx.doi.org/10.1074/jbc.273.45.29411)

- 21. Wang D, Westerheide SD, Hanson JL, et al. Tumor necrosis factor alpha-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. J Biol Chem 2000;275:32592–32597. [PubMed: 10938077]doi: [10.1074/jbc.M001358200](http://dx.doi.org/10.1074/jbc.M001358200)
- 22. Sakurai H, Chiba H, Miyoshi H, et al. IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the trans-activation domain. J Biol Chem 1999;274:30353–30356. [PubMed: 10521409] doi: [10.1074/jbc.274.43.30353](http://dx.doi.org/10.1074/jbc.274.43.30353)
- 23. Tergaonkar V, Bottero V, Ikawa M, et al. IkappaB kinase-independent IkappaBalpha degradation pathway: functional NF-kappaB activity and implications for cancer therapy. Mol Cell Biol 2003;23:8070–8083. [PubMed: 14585967]doi: [10.1128/MCB.23.22.8070-8083.2003](http://dx.doi.org/10.1128/MCB.23.22.8070-8083.2003)
- 24. Arenzana-Seisdedos F, Thompson J, Rodriguez MS, et al. Inducible nuclear expression of newly synthesized I kappa B alpha negatively regulates DNA-binding and transcriptional activities of NFkappa B. Mol Cell Biol 1995;15:2689–2696. [PubMed: 7739549]
- 25. Brown K, Park S, Kanno T, et al. Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha. Proc Natl Acad Sci USA 1993;90:2532–2536. [PubMed: 8460169]doi: [10.1073/pnas.90.6.2532](http://dx.doi.org/10.1073/pnas.90.6.2532)
- 26. Malek S, Chen Y, Huxford T, et al. IkappaBbeta, but not IkappaBalpha, functions as a classical cytoplasmic inhibitor of NF-kappaB dimers by masking both NF-kappaB nuclear localization sequences in resting cells. J Biol Chem 2001;276:45225–45235. [PubMed: 11571291]doi: [10.1074/jbc.M105865200](http://dx.doi.org/10.1074/jbc.M105865200)
- 27. Malek S, Huang DB, Huxford T, et al. X-ray crystal structure of an IkappaBbeta \times NF-kappaB p65 homodimer complex. J Biol Chem 2003;278:23094–23100. [PubMed: 12686541]doi: [10.1074/jbc.M301022200](http://dx.doi.org/10.1074/jbc.M301022200)
- 28. Huang TT, Feinberg SL, Suryanarayanan S, et al. The zinc finger domain of NEMO is selectively required for NF-kappa B activation by UV radiation and topoisomerase inhibitors. Mol Cell Biol 2002;22:5813–5825. [PubMed: 12138192]doi: [10.1128/MCB.22.16.5813-5825. 2002](http://dx.doi.org/10.1128/MCB.22.16.5813-5825.2002)
- 29. Rothwarf DM, Zandi E, Natoli G, et al. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature 1998;395:297–300. [PubMed: 9751060]doi: [10.1038/26261](http://dx.doi.org/10.1038/26261)
- 30. Zandi E, Rothwarf DM, Delhase M, et al. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell 1997;91:243–252. [PubMed: 9346241]doi: [10.1016/S0092-8674\(00\)80406-7](http://dx.doi.org/10.1016/S0092-8674%2800%2980406-7)
- 31. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J Biol Chem 1999;274:27339–27342. [PubMed: 10488062]doi: [10.1074/jbc.274.39.27339](http://dx.doi.org/10.1074/jbc.274.39.27339)
- 32. Laszlo CF, Wu S. Mechanism of UV-induced IkappaBalpha-independent activation of NF-kappaB. Photochem Photobiol 2008;84:1564–1568. [PubMed: 18627520]
- 33. Wu S, Tan M, Hu Y, et al. Ultraviolet light activates NFkappaB through translational inhibition of IkappaBalpha synthesis. J Biol Chem 2004;279:34898–34902. [PubMed: 15184376]doi: [10.1074/jbc.M405616200](http://dx.doi.org/10.1074/jbc.M405616200)
- 34. Koumenis C, Naczki C, Koritzinsky M, et al. Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha. Mol Cell Biol 2002;22:7405–7416. [PubMed: 12370288]doi: [10.1128/MCB.22.21.7405-7416.2002](http://dx.doi.org/10.1128/MCB.22.21.7405-7416.2002)
- 35. Curry HA, Clemens RA, Shah S, et al. Heat shock inhibits radiation-induced activation of NF-kappaB via inhibition of I-kappaB kinase. J Biol Chem 1999;274:23061–23067. [PubMed: 10438474]doi: [10.1074/jbc.274.33.23061](http://dx.doi.org/10.1074/jbc.274.33.23061)
- 36. Hershey JW, Asano K, Naranda T, et al. Conservation and diversity in the structure of translation initiation factor EIF3 from humans and yeast. Biochimie 1996;78:903–907. [PubMed: 9150866]doi: [10.1016/S0300-9084\(97\)86711-9](http://dx.doi.org/10.1016/S0300-9084%2897%2986711-9)
- 37. Pain VM. Initiation of protein synthesis in eukaryotic cells. Eur J Biochem 1996;236:747–771. [PubMed: 8665893]doi: [10.1111/j.1432-1033.1996.00747.x](http://dx.doi.org/10.1111/j.1432-1033.1996.00747.x)
- 38. Sudhakar A, Ramachandran A, Ghosh S, et al. Phosphorylation of serine 51 in initiation factor 2 alpha (eIF2 alpha) promotes complex formation between eIF2 alpha(P) and eIF2B and causes inhibition in the guanine nucleotide exchange activity of eIF2B. Biochemistry 2000;39:12929–12938. [PubMed: 11041858]doi: [10.1021/bi0008682](http://dx.doi.org/10.1021/bi0008682)

- 39. Deng J, Lu PD, Zhang Y, et al. Translational repression mediates activation of nuclear factor kappa B by phosphorylated translation initiation factor 2. Mol Cell Biol 2004;24:10161–10168. [PubMed: 15542827]doi: [10.1128/MCB.24.23.10161-10168.2004](http://dx.doi.org/10.1128/MCB.24.23.10161-10168.2004)
- 40. Wek RC. eIF-2 kinases: regulators of general and gene-specific translation initiation. Trends Biochem Sci 1994;19:491–496. [PubMed: 7855893]doi: [10.1016/0968-0004\(94\)90136-8](http://dx.doi.org/10.1016/0968-0004%2894%2990136-8)
- 41. Chen JJ, London IM. Regulation of protein synthesis by heme-regulated eIF-2 alpha kinase. Trends Biochem Sci 1995;20:105–108. [PubMed: 7709427]doi: [10.1016/S0968-0004\(00\)88975-6](http://dx.doi.org/10.1016/S0968-0004%2800%2988975-6)
- 42. Chefalo PJ, Oh J, Rafie-Kolpin M, et al. Heme-regulated eIF-2alpha kinase purifies as a hemoprotein. Eur J Biochem 1998;258:820–830. [PubMed: 9874252]doi: [10.1046/j.1432-1327.1998.2580820.x](http://dx.doi.org/10.1046/j.1432-1327.1998.2580820.x)
- 43. Maxwell CR, Rabinovitz M. Evidence for an inhibitor in the control of globin synthesis by hemin in a reticulocyte lysate. Biochem Biophys Res Commun 1969;35:79–85. [PubMed: 5779151]doi: [10.1016/0006-291X\(69\)90485-9](http://dx.doi.org/10.1016/0006-291X%2869%2990485-9)
- 44. Bauer BN, Rafie-Kolpin M, Lu L, et al. Multiple autophosphorylation is essential for the formation of the active and stable homodimer of heme-regulated eIF2alpha kinase. Biochemistry 2001;40:11543–11551. [PubMed: 11560503]doi: [10.1021/bi010983s](http://dx.doi.org/10.1021/bi010983s)
- 45. Rafie-Kolpin M, Chefalo PJ, Hussain Z, et al. Two heme-binding domains of heme-regulated eukaryotic initiation factor-2alpha kinase. N terminus and kinase insertion. J Biol Chem 2000;275:5171–5178. [PubMed: 10671563]doi: [10.1074/jbc.275.7.5171](http://dx.doi.org/10.1074/jbc.275.7.5171)
- 46. Rafie-Kolpin M, Han AP, Chen JJ. Autophosphorylation of threonine 485 in the activation loop is essential for attaining eIF2alpha kinase activity of HRI. Biochemistry 2003;42:6536–6544. [PubMed: 12767237]doi: [10.1021/bi034005v](http://dx.doi.org/10.1021/bi034005v)
- 47. Lu L, Han AP, Chen JJ. Translation initiation control by heme-regulated eukaryotic initiation factor 2alpha kinase in erythroid cells under cytoplasmic stresses. Mol Cell Biol 2001;21:7971–7980. [PubMed: 11689689]doi: [10.1128/MCB.21.23.7971-7980.2001](http://dx.doi.org/10.1128/MCB.21.23.7971-7980.2001)
- 48. Green SR, Mathews MB. Two RNA-binding motifs in the double-stranded RNA-activated protein kinase, DAI. Genes Dev 1992;6:2478–2490. [PubMed: 1364113]doi: [10.1101/gad.6.12b.2478](http://dx.doi.org/10.1101/gad.6.12b.2478)
- 49. Galabru J, Katze MG, Robert N, et al. The binding of double-stranded RNA and adenovirus VAI RNA to the interferon-induced protein kinase. Eur J Biochem 1989;178:581–589. [PubMed: 2912723]doi: [10.1111/j.1432-1033.1989.tb14485.x](http://dx.doi.org/10.1111/j.1432-1033.1989.tb14485.x)
- 50. Wu S, Kaufman RJ. A model for the double-stranded RNA (dsRNA)-dependent dimerization and activation of the dsRNA-activated protein kinase PKR. J Biol Chem 1997;272:1291–1296. [PubMed: 8995434]doi: [10.1074/jbc.272.2.1291](http://dx.doi.org/10.1074/jbc.272.2.1291)
- 51. Wu S, Rehemtulla A, Gupta NK, et al. A eukaryotic translation initiation factor 2-associated 67 kDa glycoprotein partially reverses protein synthesis inhibition by activated double-stranded RNAdependent protein kinase in intact cells. Biochemistry 1996;35:8275–8280. [PubMed: 8679583]doi: [10.1021/bi953028+](http://dx.doi.org/10.1021/bi953028+)
- 52. Ito T, Yang M, May WS. RAX, a cellular activator for double-stranded RNA-dependent protein kinase during stress signaling. J Biol Chem 1999;274:15427–15432. [PubMed: 10336432]doi: [10.1074/jbc.274.22.15427](http://dx.doi.org/10.1074/jbc.274.22.15427)
- 53. Patel RC, Sen GC. Identification of the double-stranded RNA-binding domain of the human interferon-inducible protein kinase. J Biol Chem 1992;267:7671–7676. [PubMed: 1373135]
- 54. Kumar A, Haque J, Lacoste J, et al. Double-stranded RNA-dependent protein kinase activates transcription factor NF-kappa B by phosphorylating I kappa B. Proc Natl Acad Sci USA 1994;91:6288–6292. [PubMed: 7912826]doi: [10.1073/pnas.91.14.6288](http://dx.doi.org/10.1073/pnas.91.14.6288)
- 55. Ishii T, Kwon H, Hiscott J, et al. Activation of the I kappa B alpha kinase (IKK) complex by doublestranded RNA-binding defective and catalytic inactive mutants of the interferon-inducible protein kinase PKR. Oncogene 2001;20:1900–1912. [PubMed: 11313938]doi: [10.1038/sj.onc.1204267](http://dx.doi.org/10.1038/sj.onc.1204267)
- 56. Gil J, Rullas J, Garcia MA, et al. The catalytic activity of dsRNA-dependent protein kinase, PKR, is required for NF-kappaB activation. Oncogene 2001;20:385–394. [PubMed: 11313968]doi: [10.1038/sj.onc.1204109](http://dx.doi.org/10.1038/sj.onc.1204109)
- 57. Bonnet MC, Weil R, Dam E, et al. PKR stimulates NF-kappaB irrespective of its kinase function by interacting with the IkappaB kinase complex. Mol Cell Biol 2000;20:4532–4542. [PubMed: 10848580]doi: [10.1128/MCB.20.13.4532-4542.2000](http://dx.doi.org/10.1128/MCB.20.13.4532-4542.2000)

- 58. Gil J, Alcami J, Esteban M. Activation of NF-kappa B by the dsRNA-dependent protein kinase, PKR involves the I kappa B kinase complex. Oncogene 2000;19:1369–1378. [PubMed: 10723127]doi: [10.1038/sj.onc.1203448](http://dx.doi.org/10.1038/sj.onc.1203448)
- 59. Harding HP, Zhang Y, Ron D. Protein translation and folding are coupled by an endoplasmicreticulum-resident kinase. Nature 1999;397:271–274. [PubMed: 9930704]doi: [10.1038/16729](http://dx.doi.org/10.1038/16729)
- 60. Kaufman RJ. Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev 1999;13:1211–1233. [PubMed: 10346810]doi: [10.1101/gad.13.10.1211](http://dx.doi.org/10.1101/gad.13.10.1211)
- 61. Sonenberg, N.; Hershey, JWB.; Mathews, M. Translational control of gene expression. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 2000. p x, 1020 pp
- 62. Brostrom CO, Bocckino SB, Brostrom MA. Identification of a $Ca²⁺$ requirement for protein synthesis in eukaryotic cells. J Biol Chem 1983;258:14390–14399. [PubMed: 6315727]
- 63. Gething MJ, Sambrook J. Protein folding in the cell. Nature 1992;355:33–45. [PubMed: 1731198] doi: [10.1038/355033a0](http://dx.doi.org/10.1038/355033a0)
- 64. Brostrom CO, Brostrom MA. Regulation of translational initiation during cellular responses to stress. Prog Nucleic Acid Res Mol Biol 1998;58:79–125. [PubMed: 9308364]doi: [10.1016/S0079-6603\(08\)60034-3](http://dx.doi.org/10.1016/S0079-6603%2808%2960034-3)
- 65. Shi Y, Vattem KM, Sood R, et al. Identification and characterization of pancreatic eukaryotic initiation factor 2 alpha-subunit kinase, PEK, involved in translational control. Mol Cell Biol 1998;18:7499– 7509. [PubMed: 9819435]
- 66. Jiang HY, Wek SA, McGrath BC, et al. Phosphorylation of the alpha subunit of eukaryotic initiation factor 2 is required for activation of NF-kappaB in response to diverse cellular stresses. Mol Cell Biol 2003;23:5651–5663. [PubMed: 12897138]doi: [10.1128/MCB.23.16.5651-5663.2003](http://dx.doi.org/10.1128/MCB.23.16.5651-5663.2003)
- 67. Imaizumi K, Tohyama M. The regulation of unfolded protein response by OASIS, a transmembrane bZIP transcription factor, in astrocytes. Nippon Yakurigaku Zasshi 2004;124:383–390. [PubMed: 15572842]doi: [10.1254/fpj.124.383](http://dx.doi.org/10.1254/fpj.124.383)
- 68. Wu S, Hu Y, Wang JL, et al. Ultraviolet light inhibits translation through activation of the unfolded protein response kinase PERK in the lumen of the endoplasmic reticulum. J Biol Chem 2002;277:18077–18083. [PubMed: 11877419]doi: [10.1074/jbc.M110164200](http://dx.doi.org/10.1074/jbc.M110164200)
- 69. Pahl HL, Baeuerle PA. Activation of NF-kappa B by ER stress requires both Ca^{2+} and reactive oxygen intermediates as messengers. FEBS Lett 1996;392:129–136. [PubMed: 8772190]doi: [10.1016/0014-5793\(96\)00800-9](http://dx.doi.org/10.1016/0014-5793%2896%2900800-9)
- 70. Berlanga JJ, Santoyo J, De Haro C. Characterization of a mammalian homolog of the GCN2 eukaryotic initiation factor 2alpha kinase. Eur J Biochem 1999;265:754–762. [PubMed: 10504407]doi: [10.1046/j.1432-1327.1999.00780.x](http://dx.doi.org/10.1046/j.1432-1327.1999.00780.x)
- 71. Sood R, Porter AC, Olsen D, et al. A mammalian homologue of GCN2 protein kinase important for translational control by phosphorylation of eukaryotic initiation factor-2alpha. Genetics 2000;154:787–801. [PubMed: 10655230]
- 72. Kimball SR, Antonetti DA, Brawley RM, et al. Mechanism of inhibition of peptide chain initiation by amino acid deprivation in perfused rat liver. Regulation involving inhibition of eukaryotic initiation factor 2 alpha phosphatase activity. J Biol Chem 1991;266:1969–1976. [PubMed: 1671047]
- 73. Wek RC, Jiang HY, Anthony TG. Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans 2006;34:7–11. [PubMed: 16246168]doi: [10.1042/BST0340007](http://dx.doi.org/10.1042/BST0340007)
- 74. Qiu H, Garcia-Barrio MT, Hinnebusch AG. Dimerization by translation initiation factor 2 kinase GCN2 is mediated by interactions in the C-terminal ribosome-binding region and the protein kinase domain. Mol Cell Biol 1998;18:2697–2711. [PubMed: 9566889]
- 75. Ramirez M, Wek RC, Hinnebusch AG. Ribosome association of GCN2 protein kinase, a translational activator of the GCN4 gene of *Saccharomyces cerevisiae*. Mol Cell Biol 1991;11:3027–3036. [PubMed: 2038314]
- 76. Jiang HY, Wek RC. GCN2 phosphorylation of eIF2alpha activates NF-kappaB in response to UV irradiation. Biochem J 2005;385:371–380. [PubMed: 15355306]doi: [10.1042/BJ20041348](http://dx.doi.org/10.1042/BJ20041348)
- 77. Rosenwald IB, Koifman L, Savas L, et al. Expression of the translation initiation factors eIF-4E and eIF-2* is frequently increased in neoplastic cells of Hodgkin lymphoma. Hum Pathol 2008;39:910– 916. [PubMed: 18234281]doi: [10.1016/j.humpath.2007.10.021](http://dx.doi.org/10.1016/j.humpath.2007.10.021)

- 78. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002;109:S81–S96. [PubMed: 11983155]doi: [10.1016/S0092-8674\(02\)00703-1](http://dx.doi.org/10.1016/S0092-8674%2802%2900703-1)
- 79. Mathes E, O'Dea EL, Hoffmann A, et al. NF-kappaB dictates the degradation pathway of IkappaBalpha. EMBO J 2008;27:1357–1367. [PubMed: 18401342]doi: [10.1038/emboj.2008.73](http://dx.doi.org/10.1038/emboj.2008.73)
- 80. Krappmann D, Wulczyn FG, Scheidereit C. Different mechanisms control signal-induced degradation and basal turnover of the NF-kappaB inhibitor IkappaB alpha in vivo. EMBO J 1996;15:6716–6726. [PubMed: 8978697]
- 81. Brockman JA, Scherer DC, McKinsey TA, et al. Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation. Mol Cell Biol 1995;15:2809–2818. [PubMed: 7739562]
- 82. Whiteside ST, Ernst MK, LeBail O, et al. N- and C-terminal sequences control degradation of MAD3/ I kappa B alpha in response to inducers of NF-kappa B activity. Mol Cell Biol 1995;15:5339–5345. [PubMed: 7565683]
- 83. Traenckner EB, Pahl HL, Henkel T, et al. Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J 1995;14:2876–2883. [PubMed: 7796813]
- 84. Benkowski LA, Ravel JM, Browning KS. mRNA binding properties of wheat germ protein synthesis initiation factor 2. Biochem Biophys Res Commun 1995;214:1033–1039. [PubMed: 7575506]doi: [10.1006/bbrc.1995.2389](http://dx.doi.org/10.1006/bbrc.1995.2389)
- 85. Scherer DC, Brockman JA, Chen Z, et al. Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination. Proc Natl Acad Sci USA 1995;92:11259–11263. [PubMed: 7479976] doi: [10.1073/pnas.92.24.11259](http://dx.doi.org/10.1073/pnas.92.24.11259)
- 86. Baldi L, Brown K, Franzoso G, et al. Critical role for lysines 21 and 22 in signal-induced, ubiquitinmediated proteolysis of I kappa B-alpha. J Biol Chem 1996;271:376–379. [PubMed: 8550590]doi: [10. 1074/jbc.271.1.376](http://dx.doi.org/10.1074/jbc.271.1.376)
- 87. Rogers S, Wells R, Rechsteiner M. Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science 1986;234:364–368. [PubMed: 2876518]doi: [10.1126/science.2876518](http://dx.doi.org/10.1126/science.2876518)
- 88. Sun S, Elwood J, Greene WC. Both amino- and carboxyl-terminal sequences within I kappa B alpha regulate its inducible degradation. Mol Cell Biol 1996;16:1058–1065. [PubMed: 8622650]
- 89. Aoki T, Sano Y, Yamamoto T, et al. The ankyrin repeats but not the PEST-like sequences are required for signal-dependent degradation of IkappaBalpha. Oncogene 1996;12:1159–1164. [PubMed: 8649809]
- 90. Barroga CF, Stevenson JK, Schwarz EM, et al. Constitutive phosphorylation of I kappa B alpha by casein kinase II. Proc Natl Acad Sci USA 1995;92:7637–7641. [PubMed: 7644469]doi: [10.1073/pnas.92.17.7637](http://dx.doi.org/10.1073/pnas.92.17.7637)
- 91. Mellits KH, Hay RT, Goodbourn S. Proteolytic degradation of MAD3 (I kappa B alpha) and enhanced processing of the NF-kappa B precursor p105 are obligatory steps in the activation of NF-kappa B. Nucleic Acids Res 1993;21:5059–5066. [PubMed: 8255759]doi: [10.1093/nar/21.22.5059](http://dx.doi.org/10.1093/nar/21.22.5059)
- 92. Rice NR, Ernst MK. In vivo control of NF-kappa B activation by I kappa B alpha. EMBO J 1993;12:4685–4695. [PubMed: 8223478]
- 93. Henkel T, Machleidt T, Alkalay I, et al. Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B. Nature 1993;365:182–185. [PubMed: 8371761]doi: [10.1038/365182a0](http://dx.doi.org/10.1038/365182a0)
- 94. Miyamoto S, Chiao PJ, Verma IM. Enhanced I kappa B alpha degradation is responsible for constitutive NF-kappa B activity in mature murine B-cell lines. Mol Cell Biol 1994;14:3276–3282. [PubMed: 8164680]
- 95. Pando MP, Verma IM. Signal-dependent and -independent degradation of free and NF-kappa Bbound IkappaBalpha. J Biol Chem 2000;275:21278–21286. [PubMed: 10801847]doi: [10.1074/jbc.M002532200](http://dx.doi.org/10.1074/jbc.M002532200)
- 96. Zandi E, Chen Y, Karin M. Direct phosphorylation of IkappaB by IKKalpha and IKKbeta: discrimination between free and NF-kappaB-bound substrate. Science 1998;281:1360–1363. [PubMed: 9721103]doi: [10.1126/science.281.5381.1360](http://dx.doi.org/10.1126/science.281.5381.1360)

- 97. Schwarz EM, Van Antwerp D, Verma IM. Constitutive phosphorylation of IkappaBalpha by casein kinase II occurs preferentially at serine 293: requirement for degradation of free IkappaBalpha. Mol Cell Biol 1996;16:3554–3559. [PubMed: 8668171]
- 98. Kato T Jr, Delhase M, Hoffmann A, et al. CK2 is a C-terminal IkappaB kinase responsible for NFkappaB activation during the UV response. Mol Cell 2003;12:829–839. [PubMed: 14580335]doi: [10.1016/S1097-2765\(03\)00358-7](http://dx.doi.org/10.1016/S1097-2765%2803%2900358-7)
- 99. Alvarez-Castelao B, Castano JG. Mechanism of direct degradation of IkappaBalpha by 20S proteasome. FEBS Lett 2005;579:4797–4802. [PubMed: 16098527]doi: [10.1016/j.febslet.2005.07.060](http://dx.doi.org/10.1016/j.febslet.2005.07.060)
- 100. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004;3:17–26. [PubMed: 14708018]doi: [10.1038/nrd1279](http://dx.doi.org/10.1038/nrd1279)
- 101. Jang YM, Kendaiah S, Drew B, et al. Doxorubicin treatment in vivo activates caspase-12 mediated cardiac apoptosis in both male and female rats. FEBS Lett 2004;577:483–490. [PubMed: 15556633] doi: [10.1016/j.febslet.2004.10.053](http://dx.doi.org/10.1016/j.febslet.2004.10.053)
- 102. Mandic A, Hansson J, Linder S, et al. Cisplatin induces endoplasmic reticulum stress and nucleusindependent apoptotic signaling. J Biol Chem 2003;278:9100–9106. [PubMed: 12509415]doi: [10.1074/jbc.M210284200](http://dx.doi.org/10.1074/jbc.M210284200)
- 103. Ranganathan AC, Zhang L, Adam AP, et al. Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res 2006;66:1702–1711. [PubMed: 16452230]doi: [10.1158/0008-5472.CAN-05-3092](http://dx.doi.org/10.1158/0008-5472.CAN-05-3092)
- 104. Fribley AM, Evenchik B, Zeng Q, et al. Proteasome inhibitor PS-341 induces apoptosis in cisplatinresistant squamous cell carcinoma cells by induction of Noxa. J Biol Chem 2006;281:31440–31447. [PubMed: 16928686]doi: [10.1074/jbc.M604356200](http://dx.doi.org/10.1074/jbc.M604356200)
- 105. Meurs E, Chong K, Galabru J, et al. Molecular cloning and characterization of the human doublestranded RNA-activated protein kinase induced by interferon. Cell 1990;62:379–390. [PubMed: 1695551]doi: [10.1016/0092-8674\(90\)90374-N](http://dx.doi.org/10.1016/0092-8674%2890%2990374-N)
- 106. Yeung MC, Liu J, Lau AS. An essential role for the interferon-inducible, double-stranded RNAactivated protein kinase PKR in the tumor necrosis factor-induced apoptosis in U937 cells. Proc Natl Acad Sci USA 1996;93:12451–12455. [PubMed: 8901602]doi: [10.1073/pnas.93.22.12451](http://dx.doi.org/10.1073/pnas.93.22.12451)
- 107. Bush KT, Goldberg AL, Nigam SK. Proteasome inhibition leads to a heat-shock response, induction of endoplasmic reticulum chaperones, and thermotolerance. J Biol Chem 1997;272:9086–9092. [PubMed: 9083035]doi: [10.1074/jbc.272.14.9086](http://dx.doi.org/10.1074/jbc.272.14.9086)
- 108. Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 2004;24:9695–9704. [PubMed: 15509775]doi: [10.1128/MCB.24.22.9695-9704.2004](http://dx.doi.org/10.1128/MCB.24.22.9695-9704.2004)
- 109. Lee AH, Iwakoshi NN, Anderson KC, et al. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci USA 2003;100:9946–9951. [PubMed: 12902539] doi: [10.1073/pnas.1334037100](http://dx.doi.org/10.1073/pnas.1334037100)

Lászlí and Wu Page 12

Fig. 1.

The classical NF-κB activation pathway. Stimulus induced IKK phosphorylates IκB inducing its degradation. Free NF-κB translocates to the nucleus and binds to the target DNA, while its transactivation efficiency and ability to recruit other activators is further regulated by different kinases. IκB provides feedback inhibition through expulsion of NF-κB from the nucleus. The graphical representation of the molecular network was generated through the use of Ingenuity Pathways Analysis (Ingenuity® Systems). All lines are supported by at least one reference from the literature or from information of canonical pathways stored in the Ingenuity Pathways Knowledge Base

Lászlí and Wu Page 13

Fig. 2.

The eIF2 kinase regulated signaling pathways. A number of stimuli achieve eIF2 α phosphorylation through the four known eIF2α kinases. The graphical representation of the molecular network was generated through the use of Pathway Studio 6 (Ariadne Genomics®). All lines are supported by at least one reference from previously published literature stored in the Pathway Studio database

Fig. 3.

Model for translation regulation of NF- κ B activation. The eIF2 kinases phosphorylate the α subunit of eIF2, which results in the translation inhibition of IKB synthesis. The reduction of IκB leads to the dissociation of IκB-NF-κB complex and subsequent NF-κB activation. The molecular network was depicted with CellDesigner® diagram editor

Lászlí and Wu Page 15

Table 1

Role of kinases in regulation of IκB turnover

